Score Overview
Explore the 2021 public Archive ranking →
Where Sanofi ADR has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- SNY
2007: 13.9% · 2021: 29.6% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 40.74 | — |
1 Year2025-09-29 | $ 43.25 | -5.80% |
5 Years2021-09-29 | $ 38.98 | 4.52% |
10 Years2016-09-29 | $ 25.06 | 62.58% |
20 Years2006-09-29 | $ 19.58 | 108.05% |
All Time2002-07-01 | $ 12.19 | 234.20% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2002-07-01 |
|---|---|---|---|---|---|---|
| Price | $ 40.74 | $ 43.25 | $ 38.98 | $ 25.06 | $ 19.58 | $ 12.19 |
| Return | — | -5.80% | 4.52% | 62.58% | 108.05% | 234.20% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in EUR
| Year | |||
|---|---|---|---|
| TTM | € 48.91B | € 3.95B | € 6.35B |
| 2025 | € 46.71B | € 7.81B | € 8.46B |
| 2024 | € 44.28B | € 5.56B | € 7.92B |
| 2023 | € 41.61B | € 5.40B | € 8.71B |
| 2022 | € 40.56B | € 8.37B | € 12.73B |
| 2021 | € 39.17B | € 6.22B | € 10.09B |
| 2020 | € 37.36B | € 12.29B | € 13.91B |
| 2019 | € 37.63B | € 2.75B | € 9.85B |
| 2018 | € 35.67B | € 4.30B | € 7.12B |
| 2017 | € 36.22B | € 8.41B | € 10.31B |
| 2016 | € 34.69B | € 4.70B | € 10.38B |
| 2015 | € 34.86B | € 4.28B | € 9.24B |
| 2014 | € 31.99B | € 4.39B | € 7.55B |
| 2013 | € 31.29B | € 3.71B | € 8.44B |
| 2012 | € 35.95B | € 4.88B | € 6.55B |
| 2011 | € 35.05B | € 5.64B | € 4.29B |
| 2010 | € 34.03B | € 5.46B | € 6.51B |
| 2009 | € 30.74B | € 5.26B | € 4.96B |
| 2008 | € 28.81B | € 3.85B | € 4.62B |
| 2007 | € 29.20B | € 5.26B | € 1.79B |
| 2006 | € 29.48B | € 4.00B | € 1.26B |
| 2005 | € 28.49B | € 2.25B | € 1.56B |
| 2004 | € 15.72B | € 1.98B | € 2.48B |
| 2003 | € 8.03B | € 2.07B | € 3.37B |
| IPO2002 | € 7.45B | € 1.76B | € 3.09B |
Sanofi ADR fundamental performance
Between 2020 and 2025, revenue grew from € 37.36B to € 46.71B and net income declined from € 12.29B to € 7.81B. Revenue increased in every one of those 5 years; net income in 3.
Across Sanofi ADR's full reported history, from 2002 to 2025, revenue grew from € 7.45B to € 46.71B and net income grew from € 1.76B to € 7.81B. Revenue increased in 75% of the years measured; net income in 58%.
Sanofi ADR currently holds a 20-year HDB Score of 4.7 out of 10. How the HDB Score is calculated.
Membership
Continue SNY’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
